Skip to main content

Table 6 Results using the Novagnost assays, including indeterminates, as compared to established EBV status

From: Reliability of the Siemens Enzygnost and Novagnost Epstein–Barr Virus assays for routine laboratory diagnosis: agreement with clinical diagnosis and comparison with the Merifluor Epstein–Barr Virus immunofluorescence assay

  Novagnost interpretation
Determined Indeterminate
Negative Acute infection Past infection Isolated EBNA-1 (probable past infection) Isolated VCA IgG (EBNA-1 lost, probable past infection) All positive (probable past infection) % agreement with EBV status
  Negativea (N = 39) 35 1 1 0 0 0 89.7
  Acute infection (N = 15) 0 15 0 0 0 0 100%
  Past infection (N = 464) 5 0 399 8 55 2 86b
EBV status         98.8c
         87.7d
         97.8e
         99.6f
  1. a Determination could not be made for 2 sera which did not match any of the indeterminate types listed in the table.
  2. b Agreement if all indeterminate results are included in the analysis.
  3. c Agreement if all indeterminate results are excluded from the analysis (i.e., 399/404).
  4. d Agreement if all isolated EBNA-1 results are assumed to represent past infections.
  5. e Agreement if results are considered indeterminate because they are VCA IgG+–only (isolated VCA IgG) are instead considered positive, and thus also most likely represent past infections.
  6. f Agreement if all isolated EBNA-1 and all isolated VCA IgG+ results are assumed to represent past infections.